<p>HENLIUS (02696.HK) announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Biologics License Application of HLX14 (dizocilpine, U.S. trade names: BILDYOS and BILPREVDA) for the treatment of osteoporosis in specific populations and eight other indications. After its launch, the group has cumulatively obtained approval for six products overseas</p>

02696

<p>HENLIUS announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Biologics License Application of HLX14 (dexamethasone, U.S. brand names: BILDYOS and BILPREVDA) for the treatment of osteoporosis in specific populations and eight other indications. After the launch, the group has cumulatively obtained approval for six products overseas</p>

HENLIUS HLX14 two products approved for market by the U.S. FDA